Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

C. H. Hsu, T. S. Yang, C. Hsu, H. C. Toh, R. J. Epstein, L. T. Hsiao, P. J. Chen, Z. Z. Lin, T. Y. Chao, A. L. Cheng

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Background: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population. Methods: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg-1 on day 1 and capecitabine 800 mg m-2 twice daily on days 1-14 every 3 weeks as first-line therapy.Results: A total of 45 patients were enrolled; 44 (96%) had extrahepatic metastasis and/or major vessel invasion and 30 (67%) had hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included diarrhoea (n=2, 4%), nausea/vomiting (n=1, 2%), gastrointestinal bleeding (n=4, 9%) and hand-foot syndrome (n=4, 9%). The overall response rate (RECIST) was 9% and the disease control rate was 52%. Overall, median progression-free survival (PFS) and overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of the Liver Italian Programme (CLIP) score≤3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.Conclusion: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC.

Original languageEnglish
Pages (from-to)981-986
Number of pages6
JournalBritish Journal of Cancer
Volume102
Issue number6
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Liver Neoplasms
Therapeutics
Disease-Free Survival
Hand-Foot Syndrome
Survival
Bevacizumab
Capecitabine
Hepatitis B
Nausea
Vomiting
Diarrhea
Hemorrhage
Neoplasm Metastasis
Safety
Population
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. / Hsu, C. H.; Yang, T. S.; Hsu, C.; Toh, H. C.; Epstein, R. J.; Hsiao, L. T.; Chen, P. J.; Lin, Z. Z.; Chao, T. Y.; Cheng, A. L.

In: British Journal of Cancer, Vol. 102, No. 6, 2010, p. 981-986.

Research output: Contribution to journalArticle

Hsu, C. H. ; Yang, T. S. ; Hsu, C. ; Toh, H. C. ; Epstein, R. J. ; Hsiao, L. T. ; Chen, P. J. ; Lin, Z. Z. ; Chao, T. Y. ; Cheng, A. L. / Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. In: British Journal of Cancer. 2010 ; Vol. 102, No. 6. pp. 981-986.
@article{c03c36185a9542b19d8dbe8c90cf759d,
title = "Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma",
abstract = "Background: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population. Methods: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg-1 on day 1 and capecitabine 800 mg m-2 twice daily on days 1-14 every 3 weeks as first-line therapy.Results: A total of 45 patients were enrolled; 44 (96{\%}) had extrahepatic metastasis and/or major vessel invasion and 30 (67{\%}) had hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included diarrhoea (n=2, 4{\%}), nausea/vomiting (n=1, 2{\%}), gastrointestinal bleeding (n=4, 9{\%}) and hand-foot syndrome (n=4, 9{\%}). The overall response rate (RECIST) was 9{\%} and the disease control rate was 52{\%}. Overall, median progression-free survival (PFS) and overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of the Liver Italian Programme (CLIP) score≤3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.Conclusion: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC.",
author = "Hsu, {C. H.} and Yang, {T. S.} and C. Hsu and Toh, {H. C.} and Epstein, {R. J.} and Hsiao, {L. T.} and Chen, {P. J.} and Lin, {Z. Z.} and Chao, {T. Y.} and Cheng, {A. L.}",
year = "2010",
doi = "10.1038/sj.bjc.6605580",
language = "English",
volume = "102",
pages = "981--986",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

AU - Hsu, C. H.

AU - Yang, T. S.

AU - Hsu, C.

AU - Toh, H. C.

AU - Epstein, R. J.

AU - Hsiao, L. T.

AU - Chen, P. J.

AU - Lin, Z. Z.

AU - Chao, T. Y.

AU - Cheng, A. L.

PY - 2010

Y1 - 2010

N2 - Background: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population. Methods: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg-1 on day 1 and capecitabine 800 mg m-2 twice daily on days 1-14 every 3 weeks as first-line therapy.Results: A total of 45 patients were enrolled; 44 (96%) had extrahepatic metastasis and/or major vessel invasion and 30 (67%) had hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included diarrhoea (n=2, 4%), nausea/vomiting (n=1, 2%), gastrointestinal bleeding (n=4, 9%) and hand-foot syndrome (n=4, 9%). The overall response rate (RECIST) was 9% and the disease control rate was 52%. Overall, median progression-free survival (PFS) and overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of the Liver Italian Programme (CLIP) score≤3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.Conclusion: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC.

AB - Background: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population. Methods: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg-1 on day 1 and capecitabine 800 mg m-2 twice daily on days 1-14 every 3 weeks as first-line therapy.Results: A total of 45 patients were enrolled; 44 (96%) had extrahepatic metastasis and/or major vessel invasion and 30 (67%) had hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included diarrhoea (n=2, 4%), nausea/vomiting (n=1, 2%), gastrointestinal bleeding (n=4, 9%) and hand-foot syndrome (n=4, 9%). The overall response rate (RECIST) was 9% and the disease control rate was 52%. Overall, median progression-free survival (PFS) and overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of the Liver Italian Programme (CLIP) score≤3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.Conclusion: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC.

UR - http://www.scopus.com/inward/record.url?scp=84984578313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984578313&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605580

DO - 10.1038/sj.bjc.6605580

M3 - Article

VL - 102

SP - 981

EP - 986

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -